Ibandronate
- Generic Name
- Ibandronate
- Brand Names
- Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H23NO7P2
- CAS Number
- 114084-78-5
- Unique Ingredient Identifier
- UMD7G2653W
- Background
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
...
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
- Associated Therapies
- -
Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy.
- Conditions
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 80
- Registration Number
- NCT06022237
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India
Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate
- Conditions
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 60
- Registration Number
- NCT04321837
- Locations
- 🇦🇲
Osteoporosis Center of Armenia, Yerevan, Armenia
Efficacy of Oral Ibandronate in Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Shinshu University
- Target Recruit Count
- 100
- Registration Number
- NCT03186131
- Locations
- 🇯🇵
Yukio Nakamura, Matsumoto, Nagano, Japan
A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo
- Conditions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT02948881
- Locations
- 🇺🇸
GSK Investigational Site, Duncansville, Pennsylvania, United States
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 89
- Registration Number
- NCT02739594
A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 334
- Registration Number
- NCT02716792
Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Target Recruit Count
- 171
- Registration Number
- NCT02616744
- Locations
- 🇮🇹
Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1711
- Registration Number
- NCT02604836
A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 308
- Registration Number
- NCT02598934
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 545
- Registration Number
- NCT02598453
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.